lly glp 1 drug Lilly's new GLP-1 pill is off to a 'robust' start It's not by dumb luck
Description
Int J Urol
Two years ago, one of these drugs, semaglutide, also was approved as an obesity treatment in the U.S., sparking an explosion in public interest
The relevance of this observation extends to the wider family of GPCRs, with individual effects almost certainly receptor-specific, as both -arrestin-biased 54 and G protein-biased 55 ligands have proved effective for individual receptors in preclinical studies
Michela Starace and Emanuel Raschi contributed to data interpretation, provided critical revisions, and approved the final version of the manuscript
Diabetes 62, 32613267
